Actively Recruiting

Phase Not Applicable
Age: 22Years - 85Years
All Genders
NCT04080778

Magnetic Seizure Therapy in Bipolar Depression (MST-BpD) and Treatment Resistant Depression (MST-TRD)

Led by Joao L. DeQuevedo · Updated on 2025-12-03

60

Participants Needed

1

Research Sites

174 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to compare the efficacy and side effects magnetic seizure therapy (MST) and electroconvulsive therapy (ECT) in Bipolar Depression (MST-BpD) and Treatment Resistant Depression (MST-TRD).

CONDITIONS

Official Title

Magnetic Seizure Therapy in Bipolar Depression (MST-BpD) and Treatment Resistant Depression (MST-TRD)

Who Can Participate

Age: 22Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with Bipolar I or II current depressive episode or treatment resistant depression requiring rapid response
  • Adults aged 22 to 85 years
  • Both males and females of any race and ethnic group
  • Ability to provide informed consent or assent
  • Ability to follow study procedures
  • Females of reproductive potential must use highly effective contraception for at least 1 month prior and during study, and for 1 week after treatment
  • Males of reproductive potential must use effective contraception
  • Sufficient English to complete self-rated scales
  • Good general health confirmed by medical clearance
  • Stable psychotropic medication regimen for at least 6 weeks prior to study entry
Not Eligible

You will not qualify if you...

  • Implanted devices activated or controlled by physiological signals (e.g., pacemakers, defibrillators, nerve stimulators, implanted medication pumps)
  • Conductive, ferromagnetic, or magnetic-sensitive metal implants near head or treatment coil
  • Vascular, traumatic, infectious, or metabolic brain lesions
  • Sleep deprivation or alcoholism
  • Current or unstable substance use disorder except nicotine or caffeine, stable remission defined as at least 6 months
  • Pregnant or nursing
  • History of epilepsy or unexplained seizures
  • History of space-occupying intracranial pathology
  • Diseases likely to cause hemorrhage (e.g., subdural hematoma, aortic aneurysm)
  • Degenerative central nervous system diseases like dementia
  • Anesthesia contraindications including significant cardiac or medical risks
  • Body mass index over 60
  • Severe personality disorder interfering with follow-up
  • Imminent suicide risk
  • Inability to comply with study requirements
  • Terminal illness with expected survival under 12 months
  • Bipolar depression with psychotic features
  • Allergic reactions to anesthetic or induction agents
  • Participation in other clinical trials within 30 days
  • Use of disallowed medications including antiepileptics and benzodiazepines (with some exceptions) or lithium before procedure

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The University of Texas Health Science Center at Houston

Houston, Texas, United States, 77030

Actively Recruiting

Loading map...

Research Team

J

Joao L. De Quevedo, MD, PhD

CONTACT

A

Ana Ruiz

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here